Rifaximin Has No Established Role in Diverticulitis Management
Based on the highest quality guideline evidence, rifaximin should NOT be routinely used for diverticulitis prevention or treatment, as the evidence is insufficient to support its use. 1
Guideline Recommendations
The 2022 American College of Physicians (ACP) clinical guideline explicitly states that no recommendation was issued for rifaximin because the evidence was insufficient 1. This represents the most authoritative guidance available and should direct clinical practice.
The 2021 AGA Clinical Practice Update similarly does not recommend rifaximin for any indication in diverticular disease management 2.
Why Rifaximin Is Not Recommended
Insufficient Evidence
- The ACP guideline review found inadequate evidence to support rifaximin use for:
- Primary prevention of diverticulitis in patients with diverticulosis
- Secondary prevention of recurrent diverticulitis
- Treatment of acute uncomplicated diverticulitis
- Symptom management in symptomatic uncomplicated diverticular disease 1
FDA-Approved Indications Do Not Include Diverticulitis
The FDA label for rifaximin (Xifaxan) lists approved indications as:
- Travelers' diarrhea caused by E. coli
- Hepatic encephalopathy
- Irritable bowel syndrome with diarrhea 3
Diverticular disease is NOT an FDA-approved indication, meaning use in this context is off-label without supporting evidence.
The Evidence-Practice Gap
Despite the lack of guideline support, observational studies show widespread rifaximin use in clinical practice, particularly in Italy 4, 5. However, these practice patterns are not evidence-based:
- A 2024 Italian survey found 63-83.5% of physicians prescribe rifaximin for various diverticular disease scenarios 4
- This represents a significant gap between available evidence and clinical practice that should be corrected
Limited Research Data
While some retrospective studies suggest potential benefit 6, 7, these are:
- Low-quality observational data
- Not sufficient to override guideline recommendations
- Require confirmation through rigorous randomized controlled trials 5, 8
What TO Do Instead
For preventing recurrent diverticulitis, focus on evidence-based interventions 2:
- High-quality diet
- Normal body mass index maintenance
- Regular physical activity
- Smoking cessation
- Avoid NSAIDs (except aspirin for cardiovascular prevention)
For acute uncomplicated diverticulitis in immunocompetent patients:
- Antibiotics can be used selectively rather than routinely 2
- Standard antibiotics (not rifaximin) when indicated
For recurrent or complicated diverticulitis:
- Discuss personalized elective surgery based on disease severity, patient preferences, and individual risk-benefit assessment 1
Clinical Pitfall to Avoid
Do not prescribe rifaximin for diverticular disease based on anecdotal experience or regional practice patterns. The absence of guideline support and FDA approval, combined with insufficient evidence, means this represents non-evidence-based care that may expose patients to unnecessary costs and potential antibiotic resistance without proven benefit.